Transvenous lead placement in the myocardium and determination of the electrical capture threshold
Permanent pacemaker implantation begins with venous access — the corridor through which a flexible, insulated lead is threaded from the chest wall, through the superior vena cava, into the right atrium, across the tricuspid valve, and finally into the right ventricle. Every subsequent step of pacing therapy depends on a stable, low-friction path being established here.
Three veins are commonly used to introduce pacing leads into the central venous system:
• Cephalic vein cutdown: a small incision exposes the vein directly under vision; lower risk of pneumothorax and subclavian crush syndrome, but the vein is sometimes too small or thrombosed, requiring a switch to another site.
• Subclavian vein puncture (Seldinger technique): a needle is advanced under the clavicle using anatomical landmarks or ultrasound guidance, followed by guidewire, sheath, and lead. Fast and reliable, but carries a small risk of pneumothorax, hemothorax, and — over years — "subclavian crush" lead fracture between the clavicle and first rib.
• Axillary vein puncture: a lateral approach avoiding the costoclavicular space; increasingly preferred because it combines subclavian-level ease with a lower long-term lead-fracture risk.
Once a sheath is placed, a peel-away introducer allows the lead to be advanced while the sheath is withdrawn and split away, leaving the lead in place.
Under continuous fluoroscopic guidance, the physician advances the lead stylet-directed tip through a well-defined anatomical sequence:
1. Superior vena cava (SVC) — a relatively straight conduit; the lead is advanced with gentle rotation to avoid trauma to the vessel wall. 2. Right atrium (RA) — the lead is looped to gain the momentum and orientation needed to cross the tricuspid valve without entangling chordae tendineae or the coronary sinus os. 3. Tricuspid valve crossing — a curved stylet directs the tip inferiorly and medially; excessive force risks valve leaflet or chordal injury and resultant tricuspid regurgitation. 4. Right ventricle (RV) — the tip is steered to the target site, most commonly the RV apex (easily accessible, historically favored) or increasingly the RV septum/His-Purkinje region (more physiological activation).
Contrast venography or intracardiac electrograms may supplement fluoroscopy to confirm chamber position before fixation is attempted.
The number and placement of leads depends on the pacing indication:
• Single-chamber (VVI): one lead in the RV, used for chronic atrial fibrillation with slow ventricular rates. • Dual-chamber (DDD): one lead in the RA appendage/septum and one in the RV, preserving atrioventricular synchrony for sinus node disease or AV block. • Cardiac resynchronization therapy (CRT): adds a third lead via the coronary sinus to pace the left ventricular epicardium, for patients with heart failure and wide QRS/left bundle branch block.
Each lead is a multi-layered insulated conductor coil terminating in an electrode tip — the interface across which all subsequent capture and sensing measurements are made.
Once the lead tip reaches its target site, it must be mechanically anchored to the endocardium — reliably enough to resist dislodgement from every heartbeat, patient movement, and Valsalva strain for years to decades, while making stable electrical contact with excitable myocardium.
Active-fixation leads carry a small retractable or fixed metal helix (screw) at the tip. Once positioned against the endocardium, the physician rotates the lead body — often a set number of full turns — advancing the helix 1.5–2.3 mm into the myocardial tissue. This mechanical purchase:
• Allows precise, deliberate site selection anywhere reachable in the chamber, including the septum, RV outflow tract, or His-bundle region — not just areas with prominent trabeculae • Provides immediate, verifiable fixation — an "injury current" (ST-segment elevation) on the electrogram at the moment of screw engagement confirms myocardial contact • Is retrievable during the procedure: the helix can be unscrewed and the lead repositioned if electrical parameters are unsatisfactory
Most modern active-fixation leads incorporate a steroid-eluting collar around the helix that slowly releases dexamethasone into the surrounding tissue, blunting the local inflammatory response and the acute threshold rise that would otherwise occur.
Passive-fixation leads instead terminate in soft, pliable silicone or polyurethane tines that splay outward from the tip. As the lead is advanced into the RV apex, these tines become mechanically trapped among the trabeculae carneae — the muscular ridges lining the ventricular endocardium.
• Simpler to deploy: no rotation required, and dislodgement rates are comparably low once well-seated • Site-limited: relies on trabeculated anatomy, essentially restricting placement to the RV apex (or RA appendage for atrial leads) where trabeculae are prominent • Extraction is generally more difficult long-term, since fibrous tissue grows through and around the tines over years
The choice between active and passive fixation is guided by target chamber anatomy, the need for septal or His-bundle pacing (which mandates active fixation), and operator preference.
Regardless of fixation type, the electrode tip triggers a foreign-body response beginning within hours of implantation:
• Hours to days: local edema and inflammatory cell infiltration surround the electrode — this is the dominant cause of the early rise in capture threshold seen over the first 1–6 weeks • Weeks to months: inflammation resolves and is replaced by a thin, stable fibrous capsule encasing the electrode tip • Months onward: the capsule matures, and the threshold settles into a stable chronic plateau — usually 2–4× the true acute (intraoperative) threshold
Understanding this time course is essential: a physician measuring "threshold" at implant is capturing only the starting point of a trajectory that will rise before it stabilizes (covered in Stage 5).
A pacemaker must not only deliver pulses that capture the heart — it must also "listen" for the heart's own intrinsic electrical activity so it paces only when needed. This sensing function is verified at implant by measuring the amplitude of the local intracardiac electrogram recorded directly from the lead tip, a signal far larger and cleaner than a surface ECG.
The electrogram recorded from a pacing lead is fundamentally different from a surface ECG: because the electrodes sit millimeters from depolarizing myocardium, the signal is large (millivolts, not microvolts) and sharply localized.
• Bipolar sensing: uses two closely spaced electrodes on the same lead (tip and ring), producing a signal restricted to the tissue between them — highly specific, resistant to picking up unwanted signals from distant sources (skeletal muscle, other chambers) • Unipolar sensing: uses the lead tip against the pulse generator can as the return electrode — a much larger sensing "antenna" that is more prone to oversensing extraneous signals
The deflection generated as the wavefront of depolarization passes beneath the electrode is the intracardiac R-wave (ventricular) or P-wave (atrial); its peak-to-peak amplitude and slew rate (rate of voltage change, mV/ms) are both measured intraoperatively with a pacing system analyzer.
Once the true signal amplitude is measured, the device's sensitivity setting — the minimum voltage it will recognize as a genuine intrinsic event — is programmed with margin to spare:
• Guideline target at implant: RV R-wave ≥5 mV (ideally >8 mV), RA P-wave ≥1.5 mV (ideally >2.5 mV) • Programmed sensitivity is typically set at one-half to one-third of the measured amplitude, so that normal beat-to-beat and respiratory variation in signal size does not cause intermittent non-sensing • A larger measured amplitude allows a more conservative (numerically higher, i.e. less sensitive) sensing threshold to be programmed, reducing susceptibility to oversensing noise
Sensing errors in either direction have clinical consequences:
• Undersensing: the device fails to detect a genuine intrinsic beat (signal too small, sensitivity set too conservatively, or scar tissue attenuating signal) and may deliver a pacing pulse during native repolarization — the "R-on-T" phenomenon, which can in rare cases provoke ventricular arrhythmia.
• Oversensing: the device inappropriately detects non-cardiac or far-field signals — myopotentials from skeletal muscle, T-waves, far-field atrial signals on a ventricular channel, or even electromagnetic interference — and mistakenly withholds a needed pacing pulse, causing symptomatic pauses.
Balancing these two risks is why intraoperative electrogram measurement, careful lead positioning (avoiding scarred or infarcted tissue), and individualized sensitivity programming are all essential steps.
The capture threshold is the single most important electrical measurement of a pacing lead: the minimum stimulus — expressed as a combination of pulse amplitude (voltage) and pulse duration (width) — that reliably depolarizes the myocardium and produces a paced heartbeat. Testing it directly, at implant and at every follow-up, underlies safe and battery-efficient pacemaker programming.
The voltage required to capture the myocardium depends strongly on how long the pulse is delivered. This relationship, described by Lapicque's equation, defines the strength-duration curve:
V(pw) = Rheobase × ( 1 + Chronaxie / pw )
Where: • Rheobase — the minimum voltage that will ever capture the heart, even with an infinitely long pulse width; a property of the tissue-electrode interface • Chronaxie — the pulse width (in ms) at which the required voltage is exactly twice the rheobase; a convenient index of tissue excitability
At very short pulse widths, threshold voltage rises steeply (the myocardial membrane needs enough total charge delivered quickly). At long pulse widths, the curve flattens toward the rheobase. This is why threshold testing must always report both the voltage and the pulse width at which it was measured — a threshold number alone is meaningless.
At implant and at follow-up, threshold is measured directly:
1. Fix the pulse width (commonly 0.4 or 0.5 ms) and begin pacing at a clearly supra-threshold voltage, confirming 1:1 capture (every pulse produces a paced QRS) 2. Decrease the output in small steps (typically 0.25 V, then finer 0.1 V near threshold) while observing the surface ECG or intracardiac electrogram for continued capture 3. The threshold is the lowest voltage at which capture is still consistently present — clinically defined as the point immediately before loss of capture (an abrupt disappearance of the paced QRS complex, sometimes with an escape rhythm emerging) 4. Confirm by increasing output back up by one step and re-testing, to rule out a spurious single dropped beat
The entire curve can also be swept at multiple pulse widths to reconstruct a patient-specific strength-duration curve, rather than relying on population averages.
Capture threshold is not fixed — it responds to physiological and pharmacological conditions:
• Electrolyte disturbances: hyperkalemia markedly raises threshold and can cause loss of capture even at maximal output; hypokalemia has milder, variable effects • Antiarrhythmic drugs: Class IC agents (flecainide, propafenone) and, to a lesser degree, amiodarone can raise thresholds • Myocardial infarction or fibrosis at the lead site: scarred, non-excitable tissue under the electrode raises threshold or can cause exit block • Metabolic and acid-base status: acidosis, hypoxia, and hypothermia all tend to raise threshold • Lead maturity: acute (fresh implant) thresholds are lower than the peri-implant peak, which is lower than the eventual stable chronic value (see Stage 5)
Because of this variability, thresholds are re-checked periodically throughout the life of the device, not measured once and forgotten.
Selecting a programmed pulse width near the chronaxie minimizes the total electrical energy (and therefore battery current) needed to guarantee capture — the Weiss-Lapicque energy curve has its minimum at the chronaxie, which is why many devices default close to 0.4 ms rather than using very short or very long pulses.
A capture threshold measured on the operating table is only the first data point in a trajectory that unfolds over the following months. Programming a pacemaker safely means anticipating this drift and setting the permanent output with enough headroom — a safety margin — to guarantee capture through biological variation, without wasting battery current that could otherwise extend device longevity by years.
Capture threshold after implantation follows a characteristic three-phase curve, driven by the tissue response introduced in Stage 2:
• Acute phase (day 0): the lowest threshold of the lead's lifetime, measured intraoperatively before any inflammatory reaction has begun • Peri-implant rise (roughly 1–6 weeks): local tissue edema and inflammatory infiltrate around the electrode raise the threshold, often to 2–4× the acute value at its peak (typically around week 2–4) • Chronic plateau (from ~2–3 months onward): as inflammation resolves and a stable, thin fibrous capsule encases the tip, the threshold falls back and settles at a chronic value — still somewhat above the original acute measurement, but stable for the remaining life of the lead
Steroid-eluting electrodes blunt this rise substantially, which is why nearly all modern leads incorporate a steroid collar (Stage 2) — without it, peri-implant thresholds could transiently exceed the device's maximum output.
Because threshold varies over time and with physiological state, the pacemaker's permanent programmed output is never set exactly at the measured threshold. Standard practice (aligned with HRS/ACC pacing guidelines) is to program:
• Voltage margin: 2–3× the chronic capture threshold at the programmed pulse width (e.g., a 0.8 V chronic threshold at 0.4 ms might be programmed at 2.0–2.5 V) • Alternative fixed margin: threshold voltage + 1.0 V at the same pulse width, particularly useful when thresholds are very low • Pulse-width margin: alternatively, keep voltage fixed and double the pulse width relative to threshold
This margin absorbs the biological threshold drift described above, plus additional day-to-day variability from posture, respiration, electrolyte shifts, and drug effects — without which a patient could experience sudden, dangerous loss of capture.
Every pacing pulse draws current from the pulse generator battery, and delivered energy scales with the square of voltage (E ∝ V²/R × pulse width). Programming output far above what is truly necessary shortens battery life — potentially by years — while programming it too close to threshold risks intermittent loss of capture.
Modern devices mitigate this trade-off with automatic capture management algorithms: the device periodically re-measures threshold on its own (using a beat-to-beat search or backup safety pulse), and automatically adjusts the programmed output to track the true chronic threshold with the intended margin — reducing the need for frequent manual reprogramming while still protecting battery longevity.
Routine device follow-up — typically every 3–12 months, increasingly via remote monitoring — verifies that thresholds remain within the expected chronic range and that the programmed safety margin is still appropriate.
Programming too close to threshold risks sudden loss of capture from ordinary biological drift (a missed heartbeat in a pacemaker-dependent patient can be life-threatening); programming far above threshold needlessly drains the battery. A 2–3× safety margin, refined by periodic re-measurement, is the standard that balances both risks.